MyoKardia is a South San Francisco-based clinical-stage biopharmaceutical company that aims to develop targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company's lead product candidate is mavacamten, an orally-administered small molecule in Phase III clinical trials designed to reduce left ventricular contractility and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule in Phase IIa clinical trials designed to restore normal cardiac muscle contractility in diseased DCM hearts. The company has also developed various preclinical programs such as MYK-224 & LUS-1 for HCM treatment and ACT-1 targeting genetic DCM. MyoKardia has a collaboration with 23andMe, Inc. to better research consumer genetics and rare cardiovascular diseases.
Myokardia Inc's ticker is MYOK
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, CA
There are 51-200 employees working at Myokardia Inc
It is http://www.myokardia.com
Myokardia Inc is in the Healthcare sector
Myokardia Inc is in the Biotechnology industry
The following five companies are Myokardia Inc's industry peers: